Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04422015
Other study ID # 1R01AI150521
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 1, 2020
Est. completion date March 31, 2021

Study information

Verified date August 2023
Source Barcelona Institute for Global Health
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This project aims to disentangle the role of host immune resistance and disease tolerance in afebrile malaria infections, with the goal of guiding context-adapted tactics to target this hidden reservoir, as well as to develop new approaches to clear malaria infection and reduce its severity through host-directed therapies.


Description:

Asymptomatic Plasmodium falciparum (Pf) infections debilitate the health of affected population while representing a hidden source of parasite transmission that can compromise elimination efforts. The lack of consensus on the best strategy to deal with this asymptomatic reservoir is partly due to the poor knowledge on the biological mechanisms underlying these subclinical infections. Preliminary results in Mozambique show that afebrile adults with a Pf infection detected by rapid diagnostic tests can progress to fever (10%), clear the infection (20%) and stabilize at low-density (50%) or high-density (20%) parasitemias. The study hypothesis is that these four main trajectories are driven by antibodies against Pf variant antigens, codified by the var gene family and expressed on the surface of infected erythrocytes, which would clear the infection unless the parasites develop immune evasion mechanisms, and by tolerance factors that minimize parasite-induced pathology and sustains host homeostasis.With the overarching goal of identifying key biological factors sustaining afebrile malaria infections, this project will establish a cohort of afebrile Mozambican adults followed during one month to identify subjects who can reduce pathogen load and eventually clear the infection, those who maintain infections at high-density and afebrile levels (tolerant), and those who fail to establish disease tolerance and progress to fever. Circulating and overall parasite biomass will be quantified, and new infections will be identified during follow-up using next-generation sequencing. Clinical samples from individuals with low and high parasite densities will be used to test whether parasitological trajectories of afebrile Pf infections correlate with host antibody immunity against erythrocyte surface antigens and the transcription of Pf var genes involved in cytoadhesion and immune evasion. Cytometry by time of flight and global mass spectrometry will be applied on clinical samples from afebrile individuals with high parasite densities (tolerant) and those progressing to fever (non-tolerant) to identify leukocyte populations and metabolic pathways involved in the regulation of inflammation, tissue damage and normoglycemia that support host-parasite relationships at afebrile levels. The expected outcome of this project is the identification of key molecular drivers of afebrile Pf infections for a better understanding of the relevance of these infections in different transmission setting which may require context-specific control approaches, as well as for the development of new tools to achieve sterilizing immunity and enhance disease tolerance.


Recruitment information / eligibility

Status Completed
Enrollment 475
Est. completion date March 31, 2021
Est. primary completion date March 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Age = 18 years and =60 years - A positive RDT and microscopy for P. falciparum - Axillary temperature < 37.5ºC without history of fever during the last 24h - No danger signals for severe malaria (Impaired consciousness, respiratory distress, multiple convulsions, prostration, shock, abnormal bleeding, jaundice) - Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and - Signed informed consent after explaining the purpose of the study Exclusion Criteria: - Age <18 years or >60 years - Axillary temperature =37.5ºC - Reported pregnancy - Presence of any sign/symptom of malaria (Vomiting, diarrhea, weakness, dizziness, fainting, itching, urticarial) - Presence of any other co-existing clinical condition that would not allow the individual to be considered a "healthy" afebrile carrier - Having received antimalarial medication in the preceding 30 days.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No intervention
No intervention

Locations

Country Name City State
Mozambique Fundação Manhiça/Manhiça Health Research Center Manhiça

Sponsors (4)

Lead Sponsor Collaborator
Alfredo Mayor Centro de Investigação em Saúde de Manhiça, Stanford University, University of Florida

Country where clinical trial is conducted

Mozambique, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of individuals developing fever Development of axilary temperature higher or equal than 37.5ºC 1 month
Secondary Proportion of individuals clearing the infection Clearance of parasite infection as detected by qPCR 1 month
Secondary Proportion of individuals maintaining infections without fever Confirmed P. falciparum ifection at day 28 by qPCR 1 month
See also
  Status Clinical Trial Phase
Completed NCT00440752 - The Impact of Artemether-Lumefantrine on Genes Associated With Antimalarial Resistance N/A
Completed NCT01144702 - Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Malaria by Plasmodium Falciparum Phase 2/Phase 3
Terminated NCT00400101 - Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Peptides Phase 1
Completed NCT01350856 - Tracking Resistance to Artemisinin (TRAC) Phase 4
Completed NCT00859807 - A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects Phase 4
Completed NCT04222088 - TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
Completed NCT01115439 - Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria N/A
Completed NCT00282919 - A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria Phase 2
Completed NCT00894660 - A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects Phase 1
Completed NCT00894374 - Bioequivalence Study Comparing Artesunate Tablet To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects Phase 1
Completed NCT00493363 - Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia N/A
Completed NCT00158548 - ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan Phase 3
Withdrawn NCT04289558 - Nitrite Infusion in Children With Malaria Phase 1
Completed NCT01374126 - Azithromycin Combination Therapy for the Treatment of Severe Malaria Phase 2
Completed NCT00722150 - Artemisinin Resistance in Cambodia II N/A
Completed NCT00157833 - A Randomized Trial of Coartemether and Artekin for the Treatment of Uncomplicated Malaria in Papua, Indonesia. N/A
Completed NCT00513669 - Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania Phase 1
Completed NCT00442377 - Study to Investigate the Induction of an Protective Immune Response to Malaria N/A
Completed NCT00403260 - Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients Phase 3
Completed NCT01365598 - Evaluation of the Gametocytocidal Efficacy and Safety of Primaquine in Uncomplicated Falciparum Malaria in Uganda Phase 3